Danaher to Acquire Masimo for $180 a Share to Boost Diagnostics, Faces Integration Risks

Deal framed as diagnostics growth lever

Danaher is buying Masimo for $180 per share in cash in a transaction the companies frame as a strategic push into hospital monitoring and diagnostics. The deal values Masimo at about $9.6 billion in equity and roughly $9.9 billion enterprise value after assumed debt and net acquired cash. Danaher says it will finance the acquisition with cash on hand and debt and expects the transaction to be accretive to adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and by roughly $0.70 five years post-close, projecting Masimo will deliver high-single-digit core revenue growth over the long term.

Danaher targets Masimo to expand diagnostics and hospital monitoring

Danaher positions the acquisition as a way to accelerate its diagnostics growth and to add hospital-focused pulse oximetry and patient-monitoring hardware to its life-science and diagnostics portfolio. Masimo is known for bedside monitoring systems and noninvasive sensors that serve hospitals and clinical settings, a product mix that Danaher says complements its existing diagnostics capabilities. Management cites expected synergies as the path to compressing an initial purchase multiple of about 18 times estimated 2027 EBITDA toward 15 times, reflecting operational integration and cost savings the buyer aims to realise.

Integration, product fit and execution risks

Analysts and industry watchers highlight integration and strategic-fit challenges as the key execution risks. Masimo’s hospital-centric hardware and device-focused business model depart from Danaher’s historical emphasis on life-science tools and diagnostics consumables, requiring cross-selling, distribution alignment and technology road‑map harmonisation. Danaher’s ability to convert projected synergies, preserve Masimo’s customer relationships in acute-care settings, and align R&D and manufacturing strategies will determine whether the acquisition strengthens its diagnostics franchise or creates distraction and complexity for the buyer’s broader portfolio.

Activist campaign sets stage for sale

The transaction follows a 2024–2026 governance episode in which activist Politan Capital Management led a proxy contest that removed Masimo founder Joe Kiani as board chair, reshaping the board and precipitating strategic review. The campaign is widely seen as a factor in the company’s path to a negotiated sale.

Law firm launches probe into deal terms

Halper Sadeh LLC says it is investigating potential federal securities law violations and fiduciary breaches tied to the transaction, seeking to determine whether insiders received preferential treatment or whether disclosure or process deficiencies harmed shareholders; the firm notes it may pursue remedies on behalf of affected investors.